MBMelissa J. Beall

Melissa J. Beall

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Melissa J. Beall has a total of 152 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Feline leukemia virus lifetime study: whole blood samples increase detection of low positive cats with extended long-term survival

    by Melissa J Beall, Dana Moore, Sean Turner, Julie K Levy

    Objectives: Thousands of cats in the USA are newly diagnosed with feline leukemia virus (FeLV) each year, and known FeLV-infected cats are increasingly adopted from shelters. This study investigated optimal sample types to identify FeLV-infected cats and predictors of long-term survival in a cohort of FeLV-positive cats followed for up to 8 years after diagnosis. Methods: Previously, 127 FeLV p27 antigen-positive cats were enrolled in a prospective study. Whole blood, plasma and serum were collected at enrollment and monthly for 6 months. All sample types were tested on SNAP FIV/FeLV Combo Test (SNAP) monthly, and results from microtiter plate ELISA (PetChek) for p27 antigen and a quantitative RT-PCR (qPCR) for proviral DNA were used for confirmation and classification of infection status (high positive, low positive or cryptic/negative). After the 6-month testing phase, cats entered a lifetime survival monitoring phase. Owner-reported status in the current study extended previous survival results by 4 years. Results: Testing anticoagulated whole blood on SNAP at enrollment identified five and nine more FeLV-infected low positive cats (n = 29) than plasma or serum, respectively. Although some low positive (n = 11) cats demonstrated variable test results on SNAP with plasma and serum, others (n = 17) were SNAP positive with all three sample types and classified as low positive based on PetChek and qPCR results. After an additional 4 years of monitoring, low positive cats had not reached a median survival, with 19/29 (66%) cats still alive compared with 2/90 (2.2%) high positive cats. Conclusions and relevance: Anticoagulated whole blood on SNAP was a sensitive indicator of FeLV infection relative to plasma and serum and therefore should be the preferred diagnostic sample for FeLV antigen testing. Combining the results of whole blood antigen testing, PetChek and qPCR identified cats as high positive, low positive or cryptic/negative, with high positive cats having higher risk for early mortality. Use of these diagnostic tools facilitates the management of FeLV as a chronic condition.


  • Open Access

    Occurrence of Cystoisospora spp. and other intestinal parasites in dogs and cats with diarrhea

    by Simone Morelli, Angela Di Cesare, Donato Traversa, Chiara Astuti, Ilaria Lallone, Costantina N. Tsokana, Donatella Damiani, Melissa Beall, Jesse Buch, Daniela Do Amaral Grossi, et al.


  • Open Access

    Diagnosis of canine intestinal parasites: Improved detection of Dipylidium caninum infection through coproantigen testing

    by Susan Little, Jennifer Braff, Kathryn Duncan, David Elsemore, Rita Hanna, Jancy Hanscom, Alice Lee, Katy A. Martin, Caroline Sobotyk, Lindsay Starkey, et al.


  • Open Access

    Evaluation of Anaplasma spp. seroprevalence in dogs and association with incidence of human anaplasmosis

    by Jennifer C. Braff, Andrea Arguello-Marin, Jancy Hanscom, Jill Saucier, Melissa J. Beall, Barbara A. Qurollo, Ramaswamy Chandrashekar, Jesse Buch


  • Open Access

    Immunoassay for detection of Dipylidium caninum coproantigen in dogs and cats

    by David Elsemore, Todd Bezold, Jinming Geng, Rita Hanna, Phyllis Tyrrell, Melissa Beall

    Dipylidium caninum infections in dogs and cats are underestimated because of a lack of proglottid observations and poor recovery of parasite elements by centrifugal flotation. We developed an immunoassay that employs a pair of monoclonal antibodies to capture D. caninum–specific coproantigen in fecal extracts from dogs and cats. Real-time PCR for D. caninum DNA in perianal swabs and observation of proglottids were used as reference methods. In 6 experimentally infected dogs, parasite DNA, coproantigen, and proglottid segments were first detected at 22, 23, and 26 d post-infection, respectively. Praziquantel treatment of 3 experimentally infected dogs resulted in the elimination of both coproantigen and proglottid shedding within 1–5 d post-treatment; however, parasite DNA persisted for 14 d. Immunohistochemistry on immature and mature tapeworm segments using an antibody against the coproantigen supports the premise that the antigen is produced in mature segments. We assessed the performance of our coproantigen test in natural infections in 78 dogs from a flea-endemic area. Of the 12 antigen-positive samples, 11 were confirmed with a positive PCR test and/or proglottid observation. Finally, we evaluated a convenience sample set of 730 canine and 163 feline fecal samples obtained from a commercial diagnostic laboratory; D. caninum antigen was detected in 4.1% of the canine and 12.9% of the feline samples, whereas parasite elements were observed in only 0.028% of samples. Our coproantigen immunoassay provides a sensitive method for the detection of D. caninum infection in dogs and cats.


  • Open Access

    Use of In-Clinic Diagnostic Kits for the Detection of Seropositivity to Leishmania infantum and Other Major Vector-Borne Pathogens in Healthy Dogs

    by Simone Morelli, Anastasia Diakou, Antonio Frangipane di Regalbono, Mariasole Colombo, Giulia Simonato, Angela Di Cesare, Alessandra Passarelli, Carlo Pezzuto, Zoe Tzitzoudi, Alessandra Barlaam, et al.

    Canine Vector-Borne Diseases (CVBDs) are widespread in Europe and enzootic in many other countries. Though severe illnesses may occur, dogs living in enzootic areas often show vague or no clinical signs of CVBDs. Undiagnosed infections/co-infections in subclinically infected animals favor the spread of CVBDs and increase the risk of transmission to other animals and, in some cases, humans. This study has evaluated the exposure of dogs living in key enzootic countries, i.e., Italy and Greece, to major CVBDs via the use of in-clinic diagnostic kits. Overall, 300 privately owned dogs without/with single mild clinical signs living in different regions of Italy (n. 150) and Greece (n. 150) were included in the study. As part of a clinical examination, a blood sample was collected from each dog and subjected to two serological rapid tests, i.e., the SNAP® 4Dx®Plus (IDEXX Laboratories Inc.) for the detection of antibodies against Ehrlichia spp., Anaplasma spp., Borrelia burgdorferi s.l. and Dirofilaria immitis antigen and the SNAP® Leishmania (IDEXX Laboratories Inc.) for the detection of antibodies against Leishmania infantum. In all, 51 dogs (17%; 95% CI 12.9–21.7) were seropositive to at least 1 pathogen, i.e., 4 in Italy (2.7%; 95% CI 1.4–13.1) and 47 in Greece (31.3%; 95% CI 24–39.4). Dirofilaria immitis antigens were found in 39 dogs (13%; 95% CI 9.4–17.3), while antibodies against Ehrlichia, Anaplasma and Leishmania were detected in 25 (8.3%; 95% CI 5.5–12.1), 8 (2.7%; 95% CI 1.2–5.2) and 5 (1.7%; 95% CI 0.5–3.8) dogs, respectively. None of the dogs tested seropositive for B. burgdorferi s.l. Statistical analyses were performed to evaluate associations between exposure to CVBDs and possible risk factors. The present results indicate that dogs living in enzootic areas may be seropositive for one or more CVBDs in absence of clinical signs. Rapid kits are among first line tools for the detection of CVBDs in clinical settings, as they are cost-effective, straightforward and quick to use. Also, in-clinic tests used herein allowed detection of co-exposure to CVBDs investigated.


  • Open Access

    Evaluation of barcoded magnetic bead–based immunoassays for the simultaneous detection of feline leukemia virus antigen and antibody against feline immunodeficiency virus

    by Kathy Esty, Haylea Elmer, Salam Nassar, Anthony Ruggiero, Seema Singh, Melissa Beall, Jesse Buch

    Testing platforms that leverage automation, require minimal sample volume, and enable various tests to be performed simultaneously on a single sample have the potential to improve workflow and efficiency in veterinary diagnostic laboratories. We evaluated a barcoded magnetic bead (BMB) technology using established immunoassays for detection of feline leukemia virus (FeLV) p27 antigen and antibody against feline immunodeficiency virus (FIV). Analytical sensitivity, limit of blank, and limit of detection were used to establish a functional sensitivity of 1.00 ng/mL of inactivated FeLV antigen and 35.7 ng/mL of anti-FIV monoclonal antibody. Common interferents, such as hemoglobin, lipid, and bilirubin, were not found to interfere with the performance of the assay. Intra- and inter-assay CVs were <13% for both assays using manufactured samples. Using a set of 116 feline samples, the diagnostic accuracy of our multiplex assay was 100% compared to reference assays. Performance in a convenience set of 1,000 feline samples submitted to a commercial diagnostic laboratory revealed a proportion of positive results of 1.3% for FeLV and 3.7% for FIV. BMB technology should enable rapid screening of samples for various markers in a single immunoassay well.


  • Open Access

    An Improved Point-of-Care ELISA for the Diagnosis of Anaplasmosis and Ehrlichiosis During the Acute Phase of Tick-Borne Infections in Dogs

    by Melissa J. Beall, Celine A. Mainville, Andrea Arguello-Marin, Genevieve Clark, Christine Lemieux, Jill Saucier, Brendon Thatcher, Edward B. Breitschwerdt, Leah A. Cohn, Barbara A. Qurollo, et al.


  • Open Access

    A Comparison of Copromicroscopic and Molecular Methods for the Diagnosis of Cat Aelurostrongylosis

    by Simone Morelli, Donato Traversa, Anastasia Diakou, Mariasole Colombo, Ilaria Russi, Anton Mestek, Ramaswamy Chandrashekar, Melissa Beall, Barbara Paoletti, Raffaella Iorio, et al.

    The gold standard method for the diagnosis of cat aelurostrongylosis is the detection of Aelurostrongylus abstrusus first stage larvae with the Baermann’s examination. Nevertheless, molecular assays have shown higher diagnostic performances compared to copromicroscopy. This study evaluated the usefulness of an A. abstrusus species-specific PCR on different biological samples collected in clinical settings from 100 privately-owned cats in Italy (n. 60) and Greece (n. 40). A fecal sample was collected from each animal and a pharyngeal swab was also obtained for cats from Italy. All stool samples were subjected to flotation and Baermann’s test. The cats were categorized in three groups based on the results of copromicroscopy, i.e., Group A (n. 50 cats with A. abstrusus infection regardless of positivity for other helminths), Group B (n. 25 cats negative for A. abstrusus but positive for at least one of any other helminth), Group C (n. 25 cats negative for any helminth). DNA was extracted from individual aliquots of feces, flotation supernatant, Baermann’s sediment and the pharyngeal swab and then subjected to a PCR specific for A. abstrusus. At least one fecal aliquot or the pharyngeal swab scored positive by the A. abstrusus-specific PCR for 48/50 (96%) cats enrolled in Group A; in particular, 38/50 (76%), 35/50 (70%), 41/50 (82%) and 21/25 (84%) DNA extracts from feces, flotation supernatant, Baermann’s sediment and pharyngeal swabs were positive by PCR. These results confirm that molecular tools are highly sensitive and specific and indicate that pharyngeal swabs are the most suitable sample for molecular analysis in clinical settings.